All In Biotech

Drug Trial Radar · NCT00356915

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail.

Last checked: Nov 19, 2026Latest source record: Feb 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,381

Actual

Start

Jul 2006

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Stiefel, a GSK CompanyIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jul 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.

Conditions

  • Onychomycosis

Interventions

  • Itraconazole 100mg capsulesDrug

    Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.

  • Itraconazole 200mg tabletsDrug

    Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.

  • Placebo tabletsDrug

    Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical and Mycological Cure of Target ToenailTime frame: 1 year
  2. Complete Cure - Itraconazole Tablets Compared to Itraconazole CapsulesTime frame: 12 months

Locations

68 sites in 7 countries. Site status is shown where the registry gives one.

  • Radiant Research -Birmingham

    Birmingham, Alabama

  • University of Alabama School of Medicine

    Birmingham, Alabama

  • Radiant Research - Tucson

    Tuscon, Arizona

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • East Bay Dermatology Medical Group Inc.

    Fremont, California

  • Skin Surgey Medical Group

    San Diego, California

  • Therapeutics Clinical Research

    San Diego, California

  • University of California

    San Francisco, California

  • Radiant Research - Santa Rosa

    Santa Rosa, California

  • Meridian Skincare

    Englewood, Colorado

  • The Savin Center

    New Haven, Connecticut

  • Dr. Stephen Horwitz

    Aventure, Florida

  • International Dermatology Research Inc.

    Miami, Florida

  • FMX Research Corporation

    Miami, Florida

  • Advanced Dermatology and Cosmetic Surgery

    Ormond Beach, Florida

  • Radiant Research - St. Petersburg

    St. Petersburg, Florida

  • Radiant Research - West Palm Beach

    West Palm Beach, Florida

  • Radiant Research - Atlanta West

    Austell, Georgia

  • Gwinnett Clinical Research Center Inc.

    Snellville, Georgia

  • Northwest Clinical Trials

    Boise, Idaho

  • Radiant Research - Chicago

    Chicago, Illinois

  • Radiant Research - Kansas City

    Overland Park, Kansas

  • Dr. David Fivenson

    Ann Arbour, Michigan

  • Skin and Vein Center

    Troy, Michigan

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • VA Medical Center

    Minneapolis, Minnesota

  • Dr. Eduardo Tschen

    Albuquerque, New Mexico

  • Skin Specialty Group

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Dermatology Consulting Services

    High Point, North Carolina

  • Dermatology Clinical Research Center

    Cincinnati, Ohio

  • Radiant Research - Cincinnati

    Cincinnati, Ohio

  • Northwest Cutaneous Research

    Portland, Oregon

  • Oregon Medical Research Center

    Portland, Oregon

  • Rhode Island Hospital

    Providence, Rhode Island

  • Radiant Research - Anderson

    Anderson, South Carolina

  • Radiant Research - Greenville

    Greenville, South Carolina

  • Dr. J. M. Humeniuk

    Greer, South Carolina

  • Dermatology East

    Germantown, Tennessee

  • Dermatology Associates of Knoxville

    Knoxville, Tennessee

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.